查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1738283

克隆與誘變市場－全球產業規模、佔有率、趨勢、機會和預測，按基因類型、產品類型、技術、應用、最終用戶、地區和競爭細分，2020 年至 2030 年

Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Gene Type, By Product Type, By Technique, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球克隆與誘變市場價值 26.7 億美元，預計到 2030 年將達到 75.8 億美元，複合年成長率為 18.99%。該市場正在快速成長，主要原因是克隆技術在遺傳和生殖研究等領域的應用不斷擴大。涉及克隆和誘變試劑盒的產品上市數量不斷增加，以及政府對用於治療開發的幹細胞研究的投資不斷增加，進一步推動了需求。此外，全球老齡人口的成長——更容易患慢性疾病和代謝紊亂——預計將大大促進市場擴張。人們對基因治療益處和早期診斷工具的認知不斷提高，再加上對慢性病管理的醫療保健支出增加，也支持了市場的成長軌跡。此外，頭頸癌等全球疾病負擔繼續推動對用於先進治療解決方案的基因工程工具的需求。

市場概覽
預測期 2026-2030
2024年市場規模 26.7億美元
2030年市場規模 75.8億美元
2025-2030 年複合年成長率 18.99%
成長最快的領域 誘變試劑盒
最大的市場 北美洲

關鍵市場促進因素

生物技術和製藥行業對基因工程產品的需求不斷成長

主要市場挑戰

基因操作的倫理和監管問題

主要市場趨勢

人工智慧在基因工程工作流程中的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球複製與誘變市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依基因類型（標準、複雜）
    • 依產品類型（克隆試劑盒、誘變試劑盒）
    • 按技術（拓樸 PCR 克隆、平端克隆、無縫克隆、定點突變、其他）
    • 按應用（基因合成、基因表現、基因治療、疫苗研究、其他）
    • 按最終用戶（製藥和生物技術公司、學術和研究機構、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依基因類型
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按地區

第6章：北美克隆與誘變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲克隆與誘變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太克隆與誘變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美克隆與誘變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東與非洲克隆與誘變市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 13 章：全球克隆與誘變市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 15 章：競爭格局

  • Agilent Technologies, Inc.
  • Eurofins Scientific SE
  • Sartorius AG
  • Collecta, Inc.
  • Codex DNA Inc.
  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • TransGene Biotech Co. Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 14421

The Global Cloning & Mutagenesis Market was valued at USD 2.67 billion in 2024 and is anticipated to reach USD 7.58 billion by 2030, growing at a CAGR of 18.99%. This market is witnessing rapid growth, largely fueled by expanding applications of cloning techniques in fields such as genetic and reproductive research. The increasing number of product launches involving cloning and mutagenesis kits, along with rising governmental investment in stem cell research for therapeutic development, is further driving demand. Additionally, the global rise in the aging population-more susceptible to chronic illnesses and metabolic disorders-is expected to significantly contribute to market expansion. Heightened awareness of gene therapy benefits and early diagnostic tools, combined with increased healthcare spending on chronic disease management, also supports the market's growth trajectory. Moreover, the global burden of diseases like head and neck cancer continues to drive demand for genetic engineering tools for advanced treatment solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.67 Billion
Market Size 2030USD 7.58 Billion
CAGR 2025-203018.99%
Fastest Growing SegmentMutagenesis Kits
Largest MarketNorth America

Key Market Drivers

Rising Demand for Genetically Engineered Products in Biotechnology and Pharmaceuticals

The global demand for genetically engineered products is one of the major growth catalysts for the cloning and mutagenesis market. These technologies are vital in developing new drugs, gene therapies, vaccines, and synthetic biological products. Cloning and mutagenesis techniques allow scientists to manipulate genes for desired traits, making them indispensable in genetic research and biopharmaceutical manufacturing. Significant public investments reinforce this trend-for instance, the U.S. Department of Health and Human Services allocated over $2.5 billion to BARDA in 2023 to support advanced vaccine and therapeutic development, much of which relies on gene manipulation techniques. Similarly, under its Horizon Europe framework, the European Commission has earmarked over €1 billion for health innovation, focusing on gene-based solutions and personalized medicine.

Key Market Challenges

Ethical and Regulatory Concerns Around Genetic Manipulation

The ethical and regulatory landscape surrounding genetic engineering poses a major challenge for the cloning and mutagenesis market. Concerns about biosafety, environmental impact, and moral implications, especially in human applications like germline editing and embryonic cloning, have led to global scrutiny. While somatic cell gene editing is generally accepted, public and institutional opposition to germline modifications persists. Following incidents like the unauthorized editing of human embryos in 2018, regulatory bodies such as the WHO and UNESCO have called for stricter oversight. Regulatory inconsistencies between regions further complicate the market-while agencies like the FDA and EMA allow controlled gene therapy, other countries enforce bans on certain genetic techniques. The EU, for example, imposes rigorous regulations on GMOs, often delaying their approval. These regulatory and ethical hurdles not only slow innovation but also increase compliance costs, especially for companies operating in sensitive sectors like human therapeutics and agricultural biotechnology.

Key Market Trends

Integration of Artificial Intelligence in Genetic Engineering Workflows

The adoption of artificial intelligence in genetic research is a transformative trend in the cloning and mutagenesis market. AI and machine learning technologies are being increasingly utilized to automate gene synthesis, select optimal mutagenesis sites, design primers, and predict protein behavior after mutation. These tools help researchers conduct high-precision experiments more efficiently and cost-effectively. AI-driven analysis of large genomic datasets enables faster identification of gene targets and potential phenotypic outcomes, streamlining drug development and genetic research. Government support is also fostering this integration. For instance, the U.S. has prioritized AI in healthcare through the National Artificial Intelligence Initiative Act and allocated over $1.5 billion for related research in 2023. Similarly, Europe's Horizon Europe program promotes AI-based innovation in biotechnology. As AI systems become more advanced and widely adopted, their impact on genetic engineering is expected to enhance the reproducibility, speed, and accuracy of cloning and mutagenesis experiments across the pharmaceutical, agricultural, and research sectors.

Key Market Players

  • Agilent Technologies, Inc.
  • Eurofins Scientific SE
  • Sartorius AG
  • Collecta, Inc.
  • Codex DNA Inc.
  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • TransGene Biotech Co. Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

  • Standard
  • Complex

Cloning & Mutagenesis Market, By Product Type:

  • Cloning Kits
  • Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

  • Topo PCR Cloning
  • Blunt End Cloning
  • Seamless Cloning
  • Site-Directed Mutagenesis

Cloning & Mutagenesis Market, By Application:

  • Gene Synthesis
  • Gene Expression
  • Gene Therapy
  • Vaccine Research
  • Others

Cloning & Mutagenesis Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Others

Cloning & Mutagenesis Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cloning & Mutagenesis Market.

Available Customizations:

Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Gene Type (Standard, Complex)
    • 5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
    • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
    • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Gene Type
    • 5.3.2. By Product Type
    • 5.3.3. By Technique
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Cloning & Mutagenesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Gene Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technique
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cloning & Mutagenesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Gene Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Technique
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Gene Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Technique
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Gene Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Technique
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Gene Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technique
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cloning & Mutagenesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Gene Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Germany Cloning & Mutagenesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Gene Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Gene Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Gene Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Technique
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Gene Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Technique
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Cloning & Mutagenesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Gene Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technique
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cloning & Mutagenesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Gene Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Cloning & Mutagenesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Gene Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Gene Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Gene Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Gene Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Cloning & Mutagenesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Gene Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technique
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cloning & Mutagenesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Gene Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Cloning & Mutagenesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Gene Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Cloning & Mutagenesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Gene Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Cloning & Mutagenesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Gene Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technique
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cloning & Mutagenesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Gene Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Cloning & Mutagenesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Gene Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Cloning & Mutagenesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Gene Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Cloning & Mutagenesis Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products/Services

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Eurofins Scientific SE
  • 15.3. Sartorius AG
  • 15.4. Collecta, Inc.
  • 15.5. Codex DNA Inc.
  • 15.6. Lonza Group AG
  • 15.7. Charles River Laboratories International, Inc.
  • 15.8. TransGene Biotech Co. Ltd.
  • 15.9. Takara Bio, Inc.
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer